Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers
…, L Billingham, C Steward, C Crawley… - The Journal of …, 2005 - rupress.org
Stem cell transplantation is used widely in the management of a range of diseases of the
hemopoietic system. Patients are immunosuppressed profoundly in the early posttransplant …
hemopoietic system. Patients are immunosuppressed profoundly in the early posttransplant …
[HTML][HTML] Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
P Connick, M Kolappan, C Crawley… - The Lancet …, 2012 - thelancet.com
Background More than half of patients with multiple sclerosis have progressive disease
characterised by accumulating disability. The absence of treatments for progressive multiple …
characterised by accumulating disability. The absence of treatments for progressive multiple …
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
…, M Griffiths, N Russell, J Yin, C Crawley… - Blood, The Journal …, 2012 - ashpublications.org
Strategies that augment a GVL effect without increasing the risk of GVHD are required to
improve the outcome after allogeneic stem cell transplantation (SCT). Azacitidine (AZA) up-…
improve the outcome after allogeneic stem cell transplantation (SCT). Azacitidine (AZA) up-…
[HTML][HTML] Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis
…, CS Grove, H Ponstingl, J Stephens, C Crawley… - Cell reports, 2015 - cell.com
Clonal hemopoiesis driven by leukemia-associated gene mutations can occur without
evidence of a blood disorder. To investigate this phenomenon, we interrogated 15 mutation hot …
evidence of a blood disorder. To investigate this phenomenon, we interrogated 15 mutation hot …
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by …
A Gratwohl, R Brand, J Apperley, C Crawley… - …, 2006 - haematologica.org
The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell
transplantation (HSCT) for chronic myeloid leukemia (CML). Information on the current use …
transplantation (HSCT) for chronic myeloid leukemia (CML). Information on the current use …
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the …
C Crawley, M Lalancette, R Szydlo, M Gilleece… - Blood, 2005 - ashpublications.org
We report the outcome of 229 patients who received an allograft for myeloma with reduced-intensity
conditioning (RIC) regimens from 33 centers within the European Group for Blood …
conditioning (RIC) regimens from 33 centers within the European Group for Blood …
[HTML][HTML] Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial
…, P Vyas, O Goodyear, E Tholouli, C Crawley… - Biology of Blood and …, 2016 - Elsevier
Disease relapse is the major causes of treatment failure after allogeneic stem cell
transplantation (SCT) in patients with acute myeloid leukemia (AML). As well as demonstrating …
transplantation (SCT) in patients with acute myeloid leukemia (AML). As well as demonstrating …
[HTML][HTML] Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia
…, R Salim, E Tholouli, V Potter, C Crawley… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Reduced-intensity conditioning (RIC) regimens have extended the curative
potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid …
potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid …
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
C Crawley, S Iacobelli, B Björkstrand, JF Apperley… - Blood, 2007 - ashpublications.org
Despite the widespread adoption of reduced-intensity conditioning (RIC) for myeloma, there
are few data comparing outcomes with RIC with myeloablative conditioning (MAC). We …
are few data comparing outcomes with RIC with myeloablative conditioning (MAC). We …
[HTML][HTML] Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the …
…, T Masszi, A Zander, A Békássy, C Crawley… - …, 2008 - haematologica.org
Background Long-term outcome after hematopoietic stem cell transplantation including late
transplant-related events is of increasing interest. The aim of this study was to evaluate the …
transplant-related events is of increasing interest. The aim of this study was to evaluate the …